Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24874020 | 0.72 | TBXAS1 (0.42) | TBXAS1ENPP2NAMPTIDO1CA1 | |
| SCHEMBL21355616 | 0.71 | TBXAS1 (0.43) | TBXAS1PRKCINAMPTIDO1BRD4 | |
| SCHEMBL15246478 | 0.71 | TBXAS1 (0.43) | TBXAS1PRKCINAMPTIDO1BRD4 | |
| SCHEMBL24339261 | 0.70 | TBXAS1 (0.57) | TBXAS1PRKCINAMPTIDO1BRD4 | |
| SCHEMBL29986327 | 0.68 | TBXAS1 (0.48) | TBXAS1PRKCINAMPT | |
| Hydrochloric Acid SCHEMBL15232586 | 0.68 | TBXAS1 (0.51) | TBXAS1PRKCINAMPTIDO1NR3C1 | |
| Hydrochloric Acid SCHEMBL30204477 | 0.67 | TBXAS1 (0.47) | TBXAS1PRKCINAMPTIDO1 | |
| SCHEMBL31214113 | 0.67 | ENPP2 (0.35) | TBXAS1ENPP2IDO1TDO2 | |
| SCHEMBL13931946 | 0.67 | QPCT (0.43) | TBXAS1PRKCIBRD4CREBBPKDM4E | |
| SCHEMBL24423211 | 0.67 | TBXAS1 (0.40) | TBXAS1PRKCIIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024255765-A1 | NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) | 2024-12-19 | — | — | WO | disclosed |
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| CN-118251393-A | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | 唯久生物技术(苏州)有限公司 | 2024-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400561-A1 | NOVEL SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | TBXAS1 2161/4885PRKCI 2171/4885ENPP2 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.